Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $6.62 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Soligenix Inc had its IPO on 1987-06-15 under the ticker symbol SNGX.
The company operates in the Healthcare sector and Biotechnology industry. Soligenix Inc has a staff strength of 13 employees.
Shares of Soligenix Inc opened at $2.29 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $2 - $2.42, and closed at $2.05.
This is a -10.48% slip from the previous day's closing price.
A total volume of 20,315 shares were traded at the close of the day’s session.
In the last one week, shares of Soligenix Inc have increased by +9.63%.
Soligenix Inc's Key Ratios
Soligenix Inc has a market cap of $6.62 million, indicating a price to book ratio of 22.6189 and a price to sales ratio of 30.8559.
In the last 12-months Soligenix Inc’s revenue was $858496 with a gross profit of $95628 and an EBITDA of $-15209049. The EBITDA ratio measures Soligenix Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Soligenix Inc’s operating margin was -1773.18% while its return on assets stood at -39.92% with a return of equity of -183.37%.
In Q3, Soligenix Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 10.8%.
Soligenix Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-5.83 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -1.52. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Soligenix Inc’s profitability.
Soligenix Inc stock is trading at a EV to sales ratio of 19.4906 and a EV to EBITDA ratio of -1.112. Its price to sales ratio in the trailing 12-months stood at 30.8559.
Soligenix Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $17.95 million
- Total Liabilities
- $9.67 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Soligenix Inc ended 2023 with $17.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $17.95 million while shareholder equity stood at $1.03 million.
Soligenix Inc ended 2023 with $20266.00 in deferred long-term liabilities, $9.67 million in other current liabilities, 43105.00 in common stock, $-215809891.00 in retained earnings and $0 in goodwill. Its cash balance stood at $16.87 million and cash and short-term investments were $16.87 million. The company’s total short-term debt was $3,106,165 while long-term debt stood at $6.89 million.
Soligenix Inc’s total current assets stands at $17.49 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $231114.00 compared to accounts payable of $4.16 million and inventory worth $0.
In 2023, Soligenix Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Soligenix Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Soligenix Inc stock is currently trading at $2.05 per share. It touched a 52-week high of $14.9981 and a 52-week low of $14.9981. Analysts tracking the stock have a 12-month average target price of $61.88.
Its 50-day moving average was $4.34 and 200-day moving average was $8.36 The short ratio stood at 2.24 indicating a short percent outstanding of 0%.
Around 36.6% of the company’s stock are held by insiders while 727% are held by institutions.
Frequently Asked Questions About Soligenix Inc
Similar Industry Stocks (Biotechnology)
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn’s disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.